Arcutis Biotherapeutics, Inc.
NASDAQ•ARQT
CEO: Mr. Todd Franklin Watanabe M.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-01-31
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Contact Information
3027 Townsgate Road, Suite 300, Westlake Village, CA, 91361, United States
805-418-5006
Market Cap
$2.82B
P/E (TTM)
-180.8
17.9
Dividend Yield
--
52W High
$31.77
52W Low
$11.86
52W Range
Rank61Top 91.5%
2.0
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025
Financial Dashboard
Q4 2025 Data
Revenue
$129.50M+0.00%
4-Quarter Trend
EPS
$0.14+0.00%
4-Quarter Trend
FCF
$26.19M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Product Revenue Soars Total product revenue reached $372.1M in 2025, marking a substantial 123% increase over the prior year's $166.5M.
Net Loss Significantly Reduced Net loss narrowed sharply to $16.1M in 2025 from $140.0M in 2024, reflecting strong commercial traction.
ZORYVE Portfolio Expansion Commercial launches included ZORYVE cream 0.05% (Oct 2025) and ZORYVE foam for scalp/body (May 2025).
Strong Cash Position Maintained Cash, cash equivalents, and restricted cash totaled $43.2M as of year-end 2025, despite operating cash usage.
Risk Factors
Future Capital Requirements Substantial additional financing may be required to achieve goals; failure to secure capital could delay operations.
Commercialization Dependency Business success heavily relies on successful commercialization of ZORYVE and pipeline product approvals.
Patent Litigation Exposure Facing ongoing patent infringement suit with Padagis regarding ZORYVE 0.3% ANDA filing, potentially delaying approval.
Operating Results Volatility Operating results fluctuate significantly due to many factors, making future performance difficult to predict accurately.
Outlook
Expand ZORYVE Franchise Pursuing lifecycle management, including sNDA submission for ZORYVE cream 0.05% in infants (Q2 2026).
Advance ARQ-234 Development Anticipate commencing Phase 1 study for ARQ-234 in atopic dermatitis in Q1 2026.
Assume Primary Care Sales Planning to assume responsibility for pediatric and primary care sales post-Kowa agreement termination (Jan 2026).
Grow Core ZORYVE Business Strategy focuses on establishing ZORYVE as foundational therapy for long-term dermatological solutions.
Peer Comparison
Revenue (TTM)
$1.03B
$634.21M
$588.99M
Gross Margin (Latest Quarter)
95.0%
92.8%
91.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IBRX | $8.63B | -23.6 | 64.3% | 175.0% |
| CGON | $5.43B | -30.9 | -22.9% | 0.9% |
| CELC | $5.29B | -31.4 | -179.0% | 67.3% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
25.3%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:May 5, 2026
EPS:-$0.03
|Revenue:$104.85M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data